[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
랩박스 - 형광 이미징의 모든 것
스폰서배너광고 안내  배너1 배너2 배너3
LABox-과학으로 본 코로나19 (COVID-19)
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
박연희
박연희 (Yeon Hee Park) 저자 이메일 보기
성균관대학교 의과대학, 삼성서울병원
저자CV 보기
880 KB
 
조회 570  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
열기 Authors and Affiliations

Abstract

Background
Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Methods
This multicentre, open-label, randomised, phase 2 study was done in 14 academic institutions in South Korea. Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0–2 were included. One line of previous chemotherapy for metastatic breast cancer was allowed. Patients were randomly assigned, using a random permuted block design (with a block size of two), to receive palbociclib plus combination endocrine therapy (oral exemestane 25 mg per day for 28 days and oral palbociclib 125 mg per day for 21 days every 4 weeks plus leuprolide 3·75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks). Randomisation was stratified by previous chemotherapy for metastatic breast cancer and visceral metastasis. The primary endpoint was progression-free survival. All analyses were done in a modified intention-to-treat population that excluded patients who did not receive study medication. This study is registered with ClinicalTrials.gov, NCT02592746, and is ongoing for follow-up of overall survival.

Findings
Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled, of whom 184 were randomly assigned to the palbociclib plus endocrine therapy group (n=92) or the capecitabine group (n=92). Six patients in the capecitabine group withdrew from the study before drug administration; therefore, 92 patients in the palbociclib plus endocrine therapy group and 86 patients in the capecitabine group were included in the modified intention-to-treat analyses. 46 (50%) of 92 patients in the palbociclib plus endocrine therapy group and 45 (51%) of 92 in the capecitabine group were treatment naive for metastatic breast cancer. During a median follow-up of 17 months (IQR 9–22), median progression-free survival was 20·1 months (95% CI 14·2–21·8) in the palbociclib plus endocrine therapy group versus 14·4 months (12·1–17·0) in the capecitabine group (hazard ratio 0·659 [95% CI 0·437–0·994], one-sided log-rank p=0·0235). Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 vs 14 [16%] of 86 patients). 2 (2%) patients in the palbociclib plus endocrine therapy group and 15 (17%) patients in the capecitabine group had treatment-related serious adverse events. No treatment-related deaths occurred.

Interpretation
Exemestane plus palbociclib with ovarian function suppression showed clinical benefit compared with capecitabine in terms of improved progression-free survival in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib plus exemestane with ovarian suppression is an active treatment option in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have been pretreated with tamoxifen.

Funding
Pfizer, Shinpoong, and Daewoong Korea and Takeda.

논문정보
- 형식: Research article
- 게재일: 2019년 10월 (BRIC 등록일 2019-10-25)
- 연구진: 국내연구진태극기
- 분야: Cancer Biology/Oncology
과당의 지방간 유도 기작과 장내 미생물의 역할[Nature]
장철순
발표: 장철순 (Princeton University)
일자: 2020년 6월 3일 (수) 오전 10시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
등록
 
목록
라이카코리아
관련링크
박연희 님 전체논문보기 >
관련인물
김원석 (성균관대의대/삼성서울병원)
김진호 (삼성서울병원)
남석진 (성균관대학교 의과대학)
박웅양 (성균관대학교 의과대학, 삼성...)
서철원 (성균관대학교 의과대학, 삼성...)
이수현 (Pfizer Oncology...)
이지연 (성균관의대, 삼성서울병원)
임석아 (서울대학교 의과대학)
임영혁 (성균관대학교 의과대학, 삼성...)
정경해 (울산대학교 의과대학, 서울아...)
관련분야 논문보기
Cancer Biology/Oncology

외부링크
Google (by Yeon Hee Park)
Pubmed (by Yeon Hee Park)
프리미엄 Bio일정 Bio일정 프리미엄 안내
Azure Cielo real-time PCR system 런칭 기념 본사 Webinar
SYNTHEGO CRISPR Genom Editing Virtual Seminar
SYNTHEGO CRISPR Genom Editing Virtual Seminar
날짜: 2020.06.17
Online 개최
[BRIC Webinar]코로나바이러스 감염 특성과 코로나바이러스감염증-19의 병인 기전 연구[대한바이러스학회]
[BRIC Webinar]과당의 지방간 유도 기작과 장내 미생물의 역할[Nature]
[BRIC Webinar]과당의 지방간 유도 기작과 장내 미생물의 역할[Nature]
사전접수: ~2020.06.02
날짜: 2020.06.03
Online 개최
[오송첨단의료산업진흥재단] 바이오의약품 전문인력 양성교육 2차 교육생 모집
[오송첨단의료산업진흥재단] 바이오의약품 전문인력 양성교육 2차 교육생 모집
사전접수: ~2020.06.12
날짜: 2020.06.22~08.21
장소: 충북 청주시 흥덕구 오송읍 오송생명로 123 오송첨단의료산업진흥재단
[재직자 무료교육] 충북산학융합본부 5월 교육과정 (분석기기 실습, 의약품 GMP 기본)
[재직자 무료교육] 충북산학융합본부 5월 교육과정 (분석기기 실습, 의약품 GMP 기본)
날짜: 2020.05.25~06.05
장소: 청주시 흥덕구 오송읍 오송생명1로 194-41 충북산학융합본부
2020 제약바이오 분자진단 전문인력 양성과정  공고
2020 제약바이오 분자진단 전문인력 양성과정 공고
사전접수: ~2020.06.14
날짜: 2020.07.08~08.28
장소: 서울과학기술여성새로일하기센터 (강남역 12번 출구) 및 전문기관 교육장
[고용부 재직자 무료과정] 의료기기 GMP의 이해 과정
[고용부 재직자 무료과정] 의료기기 GMP의 이해 과정
날짜: 2020.05.27~29
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실1
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
에펜도르프코리아